Abstract
Intravenous immunoglobulins (IVIGs) are used for a variety of immunologic and hematologic disorders. Hemorheologic alteration or the rapid increase of platelet counts by IVIG administration can cause thrombotic adverse events. We present a 58-year-old woman with a previous diagnosis of idiopathic thrombocytopenic purpura who developed cerebellar infarction immediately after IVIG treatment. We discuss a possible role of IVIG in cerebral ischemia and management strategies.
Copyright © 2012 National Stroke Association. Published by Elsevier Inc. All rights reserved.
MeSH terms
-
Aspirin / therapeutic use
-
Brain Infarction / chemically induced*
-
Brain Infarction / diagnosis
-
Brain Infarction / drug therapy
-
Cerebellum / blood supply*
-
Cerebellum / drug effects*
-
Cerebellum / pathology
-
Cerebral Angiography / methods
-
Female
-
Humans
-
Immunoglobulins, Intravenous / administration & dosage
-
Immunoglobulins, Intravenous / adverse effects*
-
Infusions, Intravenous
-
Magnetic Resonance Angiography
-
Magnetic Resonance Imaging
-
Middle Aged
-
Purpura, Thrombocytopenic, Idiopathic / diagnosis
-
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
-
Time Factors
-
Treatment Outcome
-
gamma-Globulins / administration & dosage
-
gamma-Globulins / adverse effects*
Substances
-
Immunoglobulins, Intravenous
-
gamma-Globulins
-
Aspirin